COLLEGIUM PHARMACEUTICAL INC (COLL) Fundamental Analysis & Valuation

NASDAQ:COLL • US19459J1043

Current stock price

35.47 USD
+0.22 (+0.62%)
At close:
35.47 USD
0 (0%)
After Hours:

This COLL fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

8

1. COLL Profitability Analysis

1.1 Basic Checks

  • In the past year COLL was profitable.
  • In the past year COLL had a positive cash flow from operations.
  • COLL had positive earnings in 4 of the past 5 years.
  • COLL had a positive operating cash flow in each of the past 5 years.
COLL Yearly Net Income VS EBIT VS OCF VS FCFCOLL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M -200M -400M

1.2 Ratios

  • With an excellent Return On Assets value of 3.79%, COLL belongs to the best of the industry, outperforming 84.46% of the companies in the same industry.
  • COLL has a Return On Equity of 20.84%. This is amongst the best in the industry. COLL outperforms 91.19% of its industry peers.
  • COLL has a Return On Invested Capital of 10.19%. This is amongst the best in the industry. COLL outperforms 89.64% of its industry peers.
  • COLL had an Average Return On Invested Capital over the past 3 years of 12.68%. This is in line with the industry average of 13.10%.
Industry RankSector Rank
ROA 3.79%
ROE 20.84%
ROIC 10.19%
ROA(3y)4.06%
ROA(5y)4.07%
ROE(3y)25.24%
ROE(5y)19.62%
ROIC(3y)12.68%
ROIC(5y)9.74%
COLL Yearly ROA, ROE, ROICCOLL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 -20 -40 -60

1.3 Margins

  • COLL's Profit Margin of 8.05% is amongst the best of the industry. COLL outperforms 83.94% of its industry peers.
  • COLL's Profit Margin has been stable in the last couple of years.
  • COLL has a Operating Margin of 23.01%. This is amongst the best in the industry. COLL outperforms 90.16% of its industry peers.
  • COLL's Operating Margin has improved in the last couple of years.
  • COLL's Gross Margin of 59.35% is fine compared to the rest of the industry. COLL outperforms 68.39% of its industry peers.
  • In the last couple of years the Gross Margin of COLL has remained more or less at the same level.
Industry RankSector Rank
OM 23.01%
PM (TTM) 8.05%
GM 59.35%
OM growth 3Y15.44%
OM growth 5Y4.89%
PM growth 3YN/A
PM growth 5Y-1.41%
GM growth 3Y8.71%
GM growth 5Y0.46%
COLL Yearly Profit, Operating, Gross MarginsCOLL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -1K -2K -3K -4K -5K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. COLL Health Analysis

2.1 Basic Checks

  • COLL has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
  • The number of shares outstanding for COLL has been increased compared to 1 year ago.
  • The number of shares outstanding for COLL has been reduced compared to 5 years ago.
  • The debt/assets ratio for COLL has been reduced compared to a year ago.
COLL Yearly Shares OutstandingCOLL Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M
COLL Yearly Total Debt VS Total AssetsCOLL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B

2.2 Solvency

  • COLL has an Altman-Z score of 1.42. This is a bad value and indicates that COLL is not financially healthy and even has some risk of bankruptcy.
  • COLL has a Altman-Z score (1.42) which is in line with its industry peers.
  • The Debt to FCF ratio of COLL is 2.47, which is a good value as it means it would take COLL, 2.47 years of fcf income to pay off all of its debts.
  • The Debt to FCF ratio of COLL (2.47) is better than 92.75% of its industry peers.
  • A Debt/Equity ratio of 2.59 is on the high side and indicates that COLL has dependencies on debt financing.
  • Looking at the Debt to Equity ratio, with a value of 2.59, COLL is doing worse than 81.87% of the companies in the same industry.
  • Although COLL's pure debt/equity ratio does not look good, it has limited outstanding debt compared to the Free Cash Flow. We will not put too much weight on the debt/equity number as it may be because of low equity, which could be a consequence of a share buyback program for instance. This needs to be investigated.
Industry RankSector Rank
Debt/Equity 2.59
Debt/FCF 2.47
Altman-Z 1.42
ROIC/WACC1.1
WACC9.27%
COLL Yearly LT Debt VS Equity VS FCFCOLL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M -200M 400M -400M 600M

2.3 Liquidity

  • COLL has a Current Ratio of 1.57. This is a normal value and indicates that COLL is financially healthy and should not expect problems in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 1.57, COLL is doing worse than 73.58% of the companies in the same industry.
  • A Quick Ratio of 1.48 indicates that COLL should not have too much problems paying its short term obligations.
  • COLL has a Quick ratio of 1.48. This is in the lower half of the industry: COLL underperforms 68.39% of its industry peers.
Industry RankSector Rank
Current Ratio 1.57
Quick Ratio 1.48
COLL Yearly Current Assets VS Current LiabilitesCOLL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. COLL Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an nice 15.66% over the past year.
  • The Earnings Per Share has been growing by 57.90% on average over the past years. This is a very strong growth
  • Looking at the last year, COLL shows a very strong growth in Revenue. The Revenue has grown by 23.62%.
  • COLL shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 20.28% yearly.
EPS 1Y (TTM)15.66%
EPS 3Y137.06%
EPS 5Y57.9%
EPS Q2Q%15.25%
Revenue 1Y (TTM)23.62%
Revenue growth 3Y18.94%
Revenue growth 5Y20.28%
Sales Q2Q%12.92%

3.2 Future

  • Based on estimates for the next years, COLL will show a decrease in Earnings Per Share. The EPS will decrease by -2.39% on average per year.
  • The Revenue is expected to grow by 1.28% on average over the next years.
EPS Next Y-0.28%
EPS Next 2Y-6.54%
EPS Next 3Y-7.26%
EPS Next 5Y-2.39%
Revenue Next Year5.8%
Revenue Next 2Y0.34%
Revenue Next 3Y-0.21%
Revenue Next 5Y1.28%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
COLL Yearly Revenue VS EstimatesCOLL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M
COLL Yearly EPS VS EstimatesCOLL Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 2 -2 4 -4 6

More info and screens

Find the best growth stocksShow best growing peers

8

4. COLL Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings ratio is 4.75, which indicates a rather cheap valuation of COLL.
  • Based on the Price/Earnings ratio, COLL is valued cheaper than 96.37% of the companies in the same industry.
  • When comparing the Price/Earnings ratio of COLL to the average of the S&P500 Index (26.86), we can say COLL is valued rather cheaply.
  • With a Price/Forward Earnings ratio of 4.77, the valuation of COLL can be described as very cheap.
  • COLL's Price/Forward Earnings ratio is rather cheap when compared to the industry. COLL is cheaper than 96.37% of the companies in the same industry.
  • The average S&P500 Price/Forward Earnings ratio is at 37.39. COLL is valued rather cheaply when compared to this.
Industry RankSector Rank
PE 4.75
Fwd PE 4.77
COLL Price Earnings VS Forward Price EarningsCOLL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40 50

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, COLL is valued cheaply inside the industry as 98.45% of the companies are valued more expensively.
  • 97.93% of the companies in the same industry are more expensive than COLL, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 3.44
EV/EBITDA 3.43
COLL Per share dataCOLL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 -10 20

4.3 Compensation for Growth

  • The excellent profitability rating of COLL may justify a higher PE ratio.
  • COLL's earnings are expected to decrease with -7.26% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)0.08
EPS Next 2Y-6.54%
EPS Next 3Y-7.26%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. COLL Dividend Analysis

5.1 Amount

  • COLL does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

COLL Fundamentals: All Metrics, Ratios and Statistics

COLLEGIUM PHARMACEUTICAL INC

NASDAQ:COLL (4/10/2026, 8:14:40 PM)

After market: 35.47 0 (0%)

35.47

+0.22 (+0.62%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-26
Earnings (Next)05-07
Inst Owners123.24%
Inst Owner Change-0.06%
Ins Owners1.88%
Ins Owner Change1.19%
Market Cap1.13B
Revenue(TTM)780.57M
Net Income(TTM)62.87M
Analysts81.67
Price Target55.25 (55.77%)
Short Float %13.78%
Short Ratio8.48
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-3.08%
Min EPS beat(2)-14.08%
Max EPS beat(2)7.92%
EPS beat(4)3
Avg EPS beat(4)-0.58%
Min EPS beat(4)-14.08%
Max EPS beat(4)7.92%
EPS beat(8)6
Avg EPS beat(8)8.51%
EPS beat(12)9
Avg EPS beat(12)-12.74%
EPS beat(16)10
Avg EPS beat(16)-13.58%
Revenue beat(2)1
Avg Revenue beat(2)3.07%
Min Revenue beat(2)-2.39%
Max Revenue beat(2)8.53%
Revenue beat(4)3
Avg Revenue beat(4)2.34%
Min Revenue beat(4)-2.39%
Max Revenue beat(4)8.53%
Revenue beat(8)4
Avg Revenue beat(8)0.58%
Revenue beat(12)5
Avg Revenue beat(12)-0.05%
Revenue beat(16)8
Avg Revenue beat(16)0.3%
PT rev (1m)0.93%
PT rev (3m)11.3%
EPS NQ rev (1m)-2.55%
EPS NQ rev (3m)-1.86%
EPS NY rev (1m)-2.32%
EPS NY rev (3m)-8.99%
Revenue NQ rev (1m)-0.95%
Revenue NQ rev (3m)-3.4%
Revenue NY rev (1m)1.83%
Revenue NY rev (3m)1.93%
Valuation
Industry RankSector Rank
PE 4.75
Fwd PE 4.77
P/S 1.44
P/FCF 3.44
P/OCF 3.42
P/B 3.73
P/tB N/A
EV/EBITDA 3.43
EPS(TTM)7.46
EY21.03%
EPS(NY)7.44
Fwd EY20.97%
FCF(TTM)10.32
FCFY29.09%
OCF(TTM)10.37
OCFY29.24%
SpS24.58
BVpS9.5
TBVpS-16.18
PEG (NY)N/A
PEG (5Y)0.08
Graham Number39.94
Profitability
Industry RankSector Rank
ROA 3.79%
ROE 20.84%
ROCE 14.76%
ROIC 10.19%
ROICexc 14.94%
ROICexgc 844.11%
OM 23.01%
PM (TTM) 8.05%
GM 59.35%
FCFM 41.97%
ROA(3y)4.06%
ROA(5y)4.07%
ROE(3y)25.24%
ROE(5y)19.62%
ROIC(3y)12.68%
ROIC(5y)9.74%
ROICexc(3y)19.7%
ROICexc(5y)15.04%
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)18.36%
ROCE(5y)14.11%
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3Y20.9%
ROICexc growth 5Y-2.38%
OM growth 3Y15.44%
OM growth 5Y4.89%
PM growth 3YN/A
PM growth 5Y-1.41%
GM growth 3Y8.71%
GM growth 5Y0.46%
F-Score7
Asset Turnover0.47
Health
Industry RankSector Rank
Debt/Equity 2.59
Debt/FCF 2.47
Debt/EBITDA 1.92
Cap/Depr 0.77%
Cap/Sales 0.22%
Interest Coverage 2.61
Cash Conversion 81.17%
Profit Quality 521.05%
Current Ratio 1.57
Quick Ratio 1.48
Altman-Z 1.42
F-Score7
WACC9.27%
ROIC/WACC1.1
Cap/Depr(3y)0.69%
Cap/Depr(5y)86.46%
Cap/Sales(3y)0.19%
Cap/Sales(5y)24.98%
Profit Quality(3y)461.5%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)15.66%
EPS 3Y137.06%
EPS 5Y57.9%
EPS Q2Q%15.25%
EPS Next Y-0.28%
EPS Next 2Y-6.54%
EPS Next 3Y-7.26%
EPS Next 5Y-2.39%
Revenue 1Y (TTM)23.62%
Revenue growth 3Y18.94%
Revenue growth 5Y20.28%
Sales Q2Q%12.92%
Revenue Next Year5.8%
Revenue Next 2Y0.34%
Revenue Next 3Y-0.21%
Revenue Next 5Y1.28%
EBIT growth 1Y5.73%
EBIT growth 3Y37.3%
EBIT growth 5Y26.16%
EBIT Next Year47.38%
EBIT Next 3Y13.35%
EBIT Next 5Y7.76%
FCF growth 1Y61.11%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y60.66%
OCF growth 3Y38.41%
OCF growth 5Y28.53%

COLLEGIUM PHARMACEUTICAL INC / COLL Fundamental Analysis FAQ

What is the ChartMill fundamental rating of COLLEGIUM PHARMACEUTICAL INC (COLL) stock?

ChartMill assigns a fundamental rating of 6 / 10 to COLL.


What is the valuation status for COLL stock?

ChartMill assigns a valuation rating of 8 / 10 to COLLEGIUM PHARMACEUTICAL INC (COLL). This can be considered as Undervalued.


How profitable is COLLEGIUM PHARMACEUTICAL INC (COLL) stock?

COLLEGIUM PHARMACEUTICAL INC (COLL) has a profitability rating of 8 / 10.


Can you provide the financial health for COLL stock?

The financial health rating of COLLEGIUM PHARMACEUTICAL INC (COLL) is 5 / 10.


What is the earnings growth outlook for COLLEGIUM PHARMACEUTICAL INC?

The Earnings per Share (EPS) of COLLEGIUM PHARMACEUTICAL INC (COLL) is expected to decline by -0.28% in the next year.